Data Insights
By Company Name
No Filter Selected
By Disease Name
No Filter Selected
By Drug Name
No Filter Selected
By Themes
No Filter Selected
Showing 2 results out of 2
Data Insights
Olvimulogene nanivacirepvec by Genelux for Non-Small Cell Lung Carcinoma: Likelihood of Approval
Olvimulogene nanivacirepvec is under clinical development by Genelux and currently in Phase I for Non-Small Cell Lung Carcinoma. According to...
Data Insights
Olvimulogene nanivacirepvec by Genelux for Endometrial Cancer: Likelihood of Approval
Olvimulogene nanivacirepvec is under clinical development by Genelux and currently in Phase III for Endometrial Cancer. According to GlobalData, Phase...